Mannitol Fresenius Kabi

Mannitol, the active ingredient in Mannitol Fresenius Kabi, is an osmotic diuretic presented as a solution for injection for intravenous use. It reduces intracranial pressure, manages cerebral edema, supports acute renal failure diuresis, and lowers intraocular pressure.

GNH USA supplies Mannitol Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and other specialized care facilities worldwide, ensuring consistent quality, regulatory compliance, reliable cold‑chain logistics and dedicated technical support for each client.

Mannitol is employed as an osmotic agent to manage conditions where fluid redistribution reduces pressure or enhances urinary output.

- Reduction of intracranial pressure: decreases cerebral edema and lowers intracranial pressure in head‑injury or neurosurgical patients. - Management of cerebral edema: facilitates removal of excess fluid from brain tissue, improving neurological outcomes. - Acute renal failure: promotes osmotic diuresis to aid clearance of waste products when kidney function is compromised. - Reduction of intraocular pressure: lowers pressure within the eye in glaucoma or ocular surgery settings.

Mannitol may cause a range of adverse reactions, most of which are related to rapid fluid shifts and electrolyte changes.

Common Side Effects: - Headache: mild to moderate discomfort often occurring during infusion. - Nausea or vomiting: gastrointestinal upset related to osmotic load. - Thirst or dry mouth: sensation of dehydration. - Transient hypotension: drop in blood pressure with rapid administration. - Electrolyte imbalance (hypernatremia): elevated serum sodium levels. - Flushing or warmth: sensation of heat at infusion site.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in lungs, especially in patients with cardiac dysfunction. - Severe electrolyte disturbances (hyper‑ or hyponatremia, hyperkalemia): may require urgent correction. - Acute renal failure worsening: especially in patients with pre‑existing kidney disease. - Anaphylactoid or allergic reactions: rash, bronchospasm, or hypotension. - Cardiac arrhythmias: irregular heart rhythms due to electrolyte shifts. - Hemolysis: destruction of red blood cells in rare cases.

Mannitol administration requires careful assessment and monitoring to minimise risks. - Renal function: evaluate baseline creatinine and urine output before infusion. - Electrolyte balance: monitor serum sodium, potassium and osmolality during therapy. - Cardiovascular status: avoid rapid infusion in patients with heart failure or unstable blood pressure. - Neurological monitoring: track intracranial pressure trends and neurological signs. - Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with several drug classes, altering fluid and electrolyte balance.

Major Interactions (Avoid): - Loop diuretics: additive osmotic diuresis may cause severe dehydration. - Insulin: hyperosmolar state can impair glucose control. - Nephrotoxic agents (e.g., aminoglycosides, contrast media): increased risk of renal impairment. - ACE inhibitors or ARBs: may potentiate hypotensive effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: enhanced blood‑pressure lowering; monitor vitals. - Thyroid hormones: altered protein binding may affect hormone levels. - Bronchodilators: possible bronchospasm in susceptible individuals.